Jim Smithy

looking forward to a great day of discussion on solid tumor cell therapy at iwCART & sharing updates on PRAME-targeted TCR-T in advanced melanoma

@sesamestreet this is very insensitive to Elmo

You rock! 💙❤️🧡💚💜

Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. ja.ma/4167rLa

@andruyeung is this a joke

Herald Square is the most underrated neighborhood I don't get why people hate it - Most convenient area in NYC (B, D, F, M, N, Q, R, 1, 2, 3 & PATH trains) – you can get anywhere in the city within 20 min - Excellent food (Keen's, Ai Fiori, Noksu, Joo Ok, Rezdora) - A great meeting spot - probably the geographic center of Manhattan - Ktown is awesome - Gyms EVERYWHERE (Equinox, Lifetime, Crunch, Planet Fitness, NYSC, Orange Theory) - Great coffee all around - possibly the most dense cluster of cafes in Manhattan - All the grocery stores and shopping you would ever need

@johntrified east side to LGA is 30 min

Paradox of living in Manhattan is it takes one hour to get to the airport no matter which airport it is or method of transportation you take

I wrote about the ambiguity in prognosis of a stage IV cancer diagnosis nowadays and the bravery our patients exhibit when they navigate that ambiguity every day. @NEJM nejm.org/doi/10.1056/NE…

Ellen was diagnosed with a rare and hard to treat #ovariancancer. Everything changed when she enrolled in a clinical trial led by Dr. Rachel Grisham, based on a lab discovery years ago by @DSolit. Watch more #SavedbyScience stories on YouTube: bit.ly/3ZLODjv

@BacardiCapital Philly ⬆️ ⬆️ ⬆️

Definitive city rankings S tier: NYC, Miami, LA, A tier: Boston, Chicago, Dallas B tier: San Francisco, Nashville, Tampa C tier: Austin, San Diego, DC D tier: Denver, Vegas, New Orleans F tier: Detroit, Philly, Charlotte, Atlanta

@emmakurz @MSKCancerCenter @MGHMedicine @MSK_DeptOfMed congrats & welcome to MSK!!

Thrilled to have matched into oncology fellowship at @MSKCancerCenter ! (w/ my amazing colleagues and friends @MGHMedicine PSP). I’m truly grateful and excited for this next chapter at @MSK_DeptOfMed, an institution that has served so many I love. Can’t wait to get started 🤍

that’s a wrap on melanoma bridge! three days tackling the most pressing questions in the field with an inspiring roster of speakers… thank you @PAscierto & colleagues for organizing

@Chrystal_Paulos @PAscierto congratulations and fantastic talk!! excited to see what’s next for Th17 adoptive cell therapy

So grateful to receive the Bridge Award 2025 at Melanoma Bridge in Napoli — truly my favorite meeting. Thank you Dr. Paolo Ascierto @PAscierto and the organizers for championing T-cell innovation and this amazing family/community.

More than a year after receiving a type of immunotherapy called tumor-infiltrating lymphocyte (#TIL) therapy, Pattie is doing well and has almost no signs of metastatic #melanoma Learn more from @jsmithymd, a melanoma medical oncologist and cellular therapist at MSK and expert in #TILtherapy. bit.ly/3X9yBP0

@JordanRaanan soooo painful

Unreal. Giants gave up 33 points in the fourth quarter. Were up 18 with just over 5 minutes remaining and took the lead again with 31 seconds to go. Not enough. Broncos 33, Giants 32

@GovKathyHochul @MetroNorth LIRR next plz

New Yorkers move fast, so should our trains. Starting on October 6th, Super Express service launches on the @MetroNorth Hudson Line, months ahead of schedule, with trips under 90 minutes. This is how we build a stronger, faster, more connected New York.

Published by ⁦@OncNewsCentral⁩ | I had a great conversation with Dr ⁦@jsmithymd⁩ & Dr Michael Postow on the latest in #Melanoma #Immunotherapy & #MolecularlyTargetedTherapy - Navigating Options ⁦@MoffittNews⁩ ⁦@MSKCancerCenter⁩ oncologynewscentral.com/video/melanoma…

Scientists conducting medical research are facing an existential crisis: Layoffs and budget cuts pushed by President Trump that, they say, jeopardize finding a cure for cancer. Ted Koppel talks with cancer patients taking part in clinical trials for treatments and vaccines, whose own contributions to finding a cure are imperiled.

🎥@jsmithymd of @MSKCancerCenter highlights the need for careful post-discharge monitoring of patients with melanoma treated with lifileucel due to risks of cytopenias. Tailored follow-up is key: 🔗 ow.ly/qver50WgfE3 @ASCO #ASCO25 #Melsm #Skcsm #ImmunoOnc

@EmilyHarrold6 @ASCO @RonanAndrewMcL1 @LochrinSarah 🇮🇪⭐️🇮🇪

Wonderful to see Irish fellows on the podium @ASCO discussing novel preoperative approaches @RonanAndrewMcL1 @LochrinSarah

Underway now in the #melanoma rapid oral abstract session at #ASCO25: Sarah E. Lochrin, MBBCh (@LochrinSarah) from @MSKCancerCenter shares interim results from the C-IT Neo trial on single-dose neoadjuvant ipilimumab + nivolumab in resectable melanoma, with CD8+ PET imaging. ➡️ 59% major pathologic response after one dose ➡️ Grade ≥3 treatment-related AEs in just 9% ➡️ CD8+ PET tracer uptake correlated with IHC, but not predictive of response #Immunotherapy #Neoadjuvant @ASCO #MoffittASCO25

Congratulations to Kathryn Arbour @KCArbourMD and colleagues showing activity of BMS-986504 in MTAP-deleted solid tumors, including lung and pancreas cancer. @MSKCancerCenter